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Chronic Obstructive Pulmonary Disease
Exacerbations: Do All Roads Lead to Rome?
To the Editor:
The Rome chronic obstructive pulmonary disease (COPD)
exacerbation proposal is a welcome step forward (1). Celli and

colleagues have attempted to revise the deﬁnition and propose a new
severity classiﬁcation, based on measurable clinical and laboratory
variables instead. The central role of healthcare use when deﬁning
exacerbations has held us back from a better understanding of these
critical events.
We agree that it is appealing to direct the deﬁnition of an
exacerbation toward causation and measurable pathophysiological
variables instead of symptoms alone (2). We also sympathize with the
concept of a genuine exacerbation being an “inﬂammatory burst”
caused by an “insult to the airways” on a background of chronic
inﬂammation. However, practical implications of narrowing acute
COPD exacerbations to these primary inﬂammatory events need to
be considered. The clinical reality is that we have no universal marker
that is speciﬁc for this implied inﬂammatory burst and that, despite a
thorough work-up, we still do not identify a cause in many
exacerbations (3). Currently, exacerbations remain a diagnosis of
exclusion. Acute exacerbations of symptoms that are induced by
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Figure 1. The BACE cohort consisted of 301 patients with chronic obstructive pulmonary disease (COPD) hospitalized for an acute COPD
exacerbation. The Rome severity criteria could not be assessed in 84 of 301 patients because of missing variables. Visual analog scale score
for dyspnea was not available in the BACE cohort, but it was assumed to be >5 in all patients. Saturation without oxygen was not available for
all patients and was replaced by PO2-to-FIO2 ratio (P/F) ,310, which corresponds to 92% saturation at ambient air. BACE = Azithromycin for
Acute Exacerbations Requiring Hospitalization; CRP = C-reactive protein; HR = heart rate; RR = respiratory rate.
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comorbidities such as heart failure or even a panic attack require a
different treatment approach. For patients, however, these events are
equally frightening and just as much part of the reality of living with
COPD. We believe that the emphasis of the Rome proposal on the
inﬂammatory paradigm may shift the focus away from such events.
Moreover, in practice, exacerbations of comorbidities and
exacerbations of airway inﬂammation are not mutually exclusive but
often coincide. Rather, we would keep the concept of an acute COPD
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exacerbation broad. Once a clinical diagnosis of a COPD
exacerbation is made, maximal effort should be undertaken to better
characterize endotypes and identify treatable traits, instead of
contemplating the correct clinical label.
The current method for severity classiﬁcation is determined by
healthcare systems. The Rome proposal instead uses the visual analog
scale for dyspnea, heart rate, respiratory rate, and C-reactive protein.
The thresholds were derived from observational cohorts of
hospitalized patients. However, this lacks speciﬁcity because most
patients treated in the outpatient setting are also tachypneic and
tachycardic and have a visual analog scale score for dyspnea greater
than 5 (4), and C-reactive protein is frequently raised in patients with
COPD exacerbations treated in the community (5). Furthermore, in
hospitalized exacerbations from the BACE (Azithromycin for Acute
Exacerbations Requiring Hospitalization) study (6), many patients
would not even meet the criteria for a moderate event (Figure 1).
Overall, the Rome proposal is a bold step forward to break the
mold of our healthcare use–based deﬁnition of COPD exacerbations.
More work is needed to continue to improve on this to deﬁne
treatable traits of exacerbations. The CICERO (Collaboration in
COPD Exacerbations) program (7) will capture all exacerbations seen
in the hospital, inclusive of worsening of comorbidities, with detailed
assessments to determine the above. 䊏
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We appreciate the positive comments of Dr. Bhatt and
Dr. Ramakrishnan and colleagues on the Rome proposal for an
updated deﬁnition and severity classiﬁcation of chronic obstructive
pulmonary disease exacerbations (ECOPD) (1).
Dr. Bhatt expresses concerns that no minimum timing threshold
was proposed for an ECOPD onset. About 50% of patients have a
symptom worsening in the hours before ECOPD onset (2, 3), whereas
the remaining 50% experience a prodrome of progressive increase of
symptoms, including cough (2, 4). Importantly, not having an onset
in the timing of ECOPD is supported by the fact that early
intervention might impact favorably on outcomes of ECOPD (3, 4). A
threshold in the change in the severity of individual or combined
symptoms has been used to differentiate day-to-day symptom
variation from the onset of an ECOPD (2); empirical research will
validate the suggested threshold values that we have proposed (1).
The Rome proposal does not regard cough as a minor symptom.
Indeed, Table 2 of the manuscript includes cough in the deﬁnition
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